{"id":11137,"date":"2025-10-05T05:58:47","date_gmt":"2025-10-05T03:58:47","guid":{"rendered":"https:\/\/oxfordwisefinance.com\/blog\/?p=11137"},"modified":"2025-10-05T05:59:00","modified_gmt":"2025-10-05T03:59:00","slug":"biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial","status":"publish","type":"post","link":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/","title":{"rendered":"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial"},"content":{"rendered":"<p><img data-recalc-dims=\"1\" decoding=\"async\" src=\"https:\/\/i0.wp.com\/dealbreaker.com\/.image\/c_fit%2Ch_800%2Cw_1200\/MjAzOTk1NzIxNzA2MjUxODM2\/nasdaq.jpg?w=1140&#038;ssl=1\" \/><\/p>\n<p><b>LB Pharmaceuticals<\/b> is on a mission to revive an older medication by presenting a lead drug candidate that is a modified iteration of a long-established <b>schizophrenia treatment<\/b> originally developed by <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/10b-deal-boosts-mercks-respiratory-prospects-with-verona-pharma\/\">Sanofi<\/a><\/b>. This innovative approach is gaining traction among investors, allowing LB Pharmaceuticals to enhance its <b>initial public offering (IPO)<\/b> and raise an impressive <b>$285 million<\/b> to fund vital clinical trials.<\/p>\n<p>The New York-based LB Pharmaceuticals initially set its IPO terms earlier this week, planning to offer over <b>16.6 million shares<\/b> priced between <b>$14<\/b> and <b>$16<\/b> each, aiming to generate approximately <b>$250 million<\/b> at the midpoint of this pricing range. However, on late Wednesday, LB Pharmaceuticals increased the offering size to <b>19 million shares<\/b>, set at <b>$15<\/b> each. These shares are set to be traded on the <b>Nasdaq<\/b> under the stock symbol <b>LBRX<\/b>.<\/p>\n<p>LB Pharmaceuticals&#8217; lead drug candidate, <b>LB-102<\/b>, is based on <b>amisulpride<\/b>, a medication that was developed in the 1980s at <b>Sanofi<\/b>. While this medication received regulatory approvals in over <b>50 countries<\/b> for treating schizophrenia, <b>Sanofi<\/b> opted not to pursue <b>FDA approval<\/b> due to the drug&#8217;s short remaining patent life, as mentioned in LB&#8217;s IPO filing.<\/p>\n<p><b>Amisulpride<\/b>, marketed under the brand name <b>Solian<\/b> by <b>Sanofi<\/b>, is an oral small molecule that functions by blocking specific dopamine receptors, particularly the <b>D2<\/b> and <b>D3<\/b> receptors. The side effects commonly associated with current dopamine receptor antagonists include drowsiness, weight gain, movement disorders, and alterations in heart rhythm. LB Pharmaceuticals claims that their modification of the molecule enhances its ability to penetrate the <b>blood-brain barrier<\/b> while keeping its binding capabilities to its targets largely unaffected.<\/p>\n<p>LB Pharmaceuticals believes that the chemical modifications made to <b>LB-102<\/b> allow for lower dosing compared to <b>amisulpride<\/b>. The company states in its filing, \u201cBy lowering the dosage, we aim to reduce the side effects typically associated with <b>amisulpride<\/b>. Furthermore, this alteration in chemical structure permits us to offer a different dosing frequency for <b>LB-102<\/b> compared to <b>amisulpride<\/b>, as we are developing it for once-daily dosing instead of the conventional twice-daily regimen of <b>amisulpride<\/b>.<\/p>\n<p>During Phase 2 testing, LB Pharmaceuticals reported that all three once-daily doses of its medication yielded statistically significant results when compared to a placebo, measured on a recognized scale for assessing <b>schizophrenia symptoms<\/b>. Adverse events reported included insomnia, headache, anxiety, and agitation, while LB noted that any weight gain was modest and did not demonstrate a clinically meaningful indication in metabolic parameters.<\/p>\n<p>LB Pharmaceuticals is preparing to advance to a <b>placebo-controlled Phase 3 clinical trial<\/b> for <b>LB-102<\/b>, which will evaluate both low and high doses of the investigational drug. The trial aims to enroll <b>400 patients<\/b>. Similar to the Phase 2 study, the primary objective of this six-week Phase 3 trial is to measure the change in scores from baseline using the standard scale for evaluating <b>schizophrenia symptoms<\/b>. LB Pharmaceuticals plans to initiate this study in the first quarter of <b>2026<\/b>, with preliminary results expected in the latter half of <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/access-the-2026-2027-fafsa-before-its-official-release\/\">2027<\/a><\/b>.<\/p>\n<p>The <b>FDA<\/b> mandates two pivotal trials to facilitate approval for a <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/lb-pharmas-ipo-to-fund-phase-3-test-of-innovative-schizophrenia-drug\/\">schizophrenia medication<\/a><\/b>. In its filing, LB Pharmaceuticals stated that, given the <b>FDA<\/b> feedback and historical data, the Phase 2 study, which included <b>359 patients<\/b>, may qualify as one of the two necessary pivotal trials. If this is the case, a successful Phase 3 trial could lead to discussions with the <b>FDA<\/b> regarding a regulatory submission in early <b>2028<\/b>. However, the <b>FDA<\/b> must first concur that the Phase 2 study meets the criteria of a pivotal trial. Furthermore, LB Pharmaceuticals believes that <b>LB-102<\/b> may have potential applications for other indications, with a Phase 2 trial in <b>bipolar depression<\/b> slated to commence in the first quarter of <b>2026<\/b>, and preliminary findings expected in early <b>2028<\/b>.<\/p>\n<p>LB Pharmaceuticals initially submitted its IPO plans last month, as the new funds are critically important for its operations. Earlier this spring, the company faced a cash flow crisis that led to a corporate restructuring and layoffs. By the end of June, LB Pharmaceuticals reported a cash position of merely <b>$14.2 million<\/b>. With the funds raised from the IPO, LB Pharmaceuticals intends to allocate approximately <b>$133 million<\/b> for the Phase 3 testing of <b>LB-102<\/b>, according to their filing. An additional <b>$25 million<\/b> is earmarked for progressing the drug through Phase 2 testing for <b>bipolar depression<\/b>. LB Pharmaceuticals is also working on developing a long-acting injectable formulation of <b>LB-102<\/b>, although the filing did not specify any financial allocations for these initiatives.<\/p>\n<p> <em>Stay updated on the latest developments in litigation, regulation, financial services trends, and mergers by subscribing to Finance Docket, a collaboration between Breaking Media publications Above the Law and Dealbreaker.<\/em><\/p>\n<p><a href=\"https:\/\/dealbreaker.com\/2025\/09\/lb-pharma-pushes-the-biotech-ipo-window-open-bagging-285m-for-key-schizophrenia-drug-trial\" rel=\"nofollow\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LB Pharmaceuticals is on a mission to revive an older medication by [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9353,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pagelayer_contact_templates":[],"_pagelayer_content":"","iawp_total_views":3,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[960,142],"tags":[],"class_list":["post-11137","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology-industry","category-finance-business","col-md-12"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biotech IPO Window Opens as LB Pharma Secures $285M for Trial - Blog - Oxford Wise Finance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial - Blog - Oxford Wise Finance\" \/>\n<meta property=\"og:description\" content=\"LB Pharmaceuticals is on a mission to revive an older medication by [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Oxford Wise Finance\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/instantpaydayloans\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-05T03:58:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-05T03:59:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/01\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oxfordwisefinance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/OxfordWiseLoans\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/\"},\"author\":{\"name\":\"Oxfordwisefinance\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"headline\":\"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial\",\"datePublished\":\"2025-10-05T03:58:47+00:00\",\"dateModified\":\"2025-10-05T03:59:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/\"},\"wordCount\":746,\"commentCount\":5,\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1\",\"articleSection\":[\"Biotechnology Industry\",\"Finance &amp; Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/\",\"name\":\"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial - Blog - Oxford Wise Finance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1\",\"datePublished\":\"2025-10-05T03:58:47+00:00\",\"dateModified\":\"2025-10-05T03:59:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\",\"name\":\"Blog - Oxford Wise Finance\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\",\"name\":\"Oxfordwisefinance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"caption\":\"Oxfordwisefinance\"},\"sameAs\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/\",\"https:\\\/\\\/www.facebook.com\\\/instantpaydayloans\",\"https:\\\/\\\/x.com\\\/https:\\\/\\\/x.com\\\/OxfordWiseLoans\"],\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial - Blog - Oxford Wise Finance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/","og_locale":"en_US","og_type":"article","og_title":"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial - Blog - Oxford Wise Finance","og_description":"LB Pharmaceuticals is on a mission to revive an older medication by [&hellip;]","og_url":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/","og_site_name":"Blog - Oxford Wise Finance","article_author":"https:\/\/www.facebook.com\/instantpaydayloans","article_published_time":"2025-10-05T03:58:47+00:00","article_modified_time":"2025-10-05T03:59:00+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/01\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1","type":"image\/jpeg"}],"author":"Oxfordwisefinance","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/OxfordWiseLoans","twitter_misc":{"Written by":false,"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/#article","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/"},"author":{"name":"Oxfordwisefinance","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"headline":"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial","datePublished":"2025-10-05T03:58:47+00:00","dateModified":"2025-10-05T03:59:00+00:00","mainEntityOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/"},"wordCount":746,"commentCount":5,"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/01\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1","articleSection":["Biotechnology Industry","Finance &amp; Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/","url":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/","name":"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial - Blog - Oxford Wise Finance","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/#primaryimage"},"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/01\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1","datePublished":"2025-10-05T03:58:47+00:00","dateModified":"2025-10-05T03:59:00+00:00","author":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"breadcrumb":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/#primaryimage","url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/01\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1","contentUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/01\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/oxfordwisefinance.com\/blog\/biotech-ipo-window-opens-as-lb-pharma-secures-285m-for-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxfordwisefinance.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Biotech IPO Window Opens as LB Pharma Secures $285M for Trial"}]},{"@type":"WebSite","@id":"https:\/\/oxfordwisefinance.com\/blog\/#website","url":"https:\/\/oxfordwisefinance.com\/blog\/","name":"Blog - Oxford Wise Finance","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxfordwisefinance.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36","name":"Oxfordwisefinance","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","caption":"Oxfordwisefinance"},"sameAs":["https:\/\/oxfordwisefinance.com\/","https:\/\/www.facebook.com\/instantpaydayloans","https:\/\/x.com\/https:\/\/x.com\/OxfordWiseLoans"],"url":"https:\/\/oxfordwisefinance.com\/blog\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/01\/Ascentage-Has-First-US-Biotech-IPO-of-2025-Raising-126M.jpg?fit=1200%2C800&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/comments?post=11137"}],"version-history":[{"count":1,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11137\/revisions"}],"predecessor-version":[{"id":11138,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11137\/revisions\/11138"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media\/9353"}],"wp:attachment":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media?parent=11137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/categories?post=11137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/tags?post=11137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}